Zhang Fang, Shi Jun-Jun, Thakur Kiran, Hu Fei, Zhang Jian-Guo, Wei Zhao-Jun
School of Food Science and Engineering, Hefei University of Technology Hefei, China.
Front Pharmacol. 2017 Mar 3;8:102. doi: 10.3389/fphar.2017.00102. eCollection 2017.
In this study, four homo/heterogenous polysaccharides (HBSS, CHSS, DASS, and CASS) extracted from peony seed dreg with respective molecular weights of 3467, 4677, 229, and 56 kDa were evaluated for anti-cancerous attributes in prostate cancer cells (Pc-3), colon cancer cells (HCT-116), human breast cancer cells (MCF-7), cervical cancer (Hela cells) and human embryonic kidney 293 (HEK 293) cells as control. Among them, CASS and DASS extracted by alkali, consisted of 34.43% , 26.39% , 21.80% and 35.77% , 19.35% , 17.77% , respectively. CASS fraction had the most significant inhibitory effects on all the cell lines used whereas HBSS had least effect. The CASS shown remarkable inhibition and cytotoxic effects in Hela cells followed by other cell lines as compared to 5-fluorouracil (5-FU). CASS arrested cell cycle in G0/G1 phase except MCF-7 cells and increased apoptotic cells percentage varied in different treated cells. CASS down regulated the expression of Cyclin A/B1/D1/E1, CDK-1/2/4/6 and p15/16/21/27 excluding p53. The notable change in expression of proteins (Cytochrome C, Bax, Bcl-2, p-Caspase-3, -8, -9, and PARP) was observed followed by Apaf-1 and Survivin. These findings indicated that CASS has an anti-cancerous potential in the treatment of human cancers which make it a potent candidate in functional foods.
在本研究中,对从牡丹籽粕中提取的四种均一/不均一多糖(HBSS、CHSS、DASS和CASS)进行了评估,其分子量分别为3467、4677、229和56 kDa,研究它们对前列腺癌细胞(Pc-3)、结肠癌细胞(HCT-116)、人乳腺癌细胞(MCF-7)、子宫颈癌细胞(Hela细胞)以及作为对照的人胚肾293(HEK 293)细胞的抗癌特性。其中,通过碱提取的CASS和DASS分别由34.43%、26.39%、21.80%以及35.77%、19.35%、17.77%组成。CASS组分对所有使用的细胞系具有最显著的抑制作用,而HBSS的作用最小。与5-氟尿嘧啶(5-FU)相比,CASS在Hela细胞中表现出显著的抑制和细胞毒性作用,其次是在其他细胞系中。CASS使细胞周期停滞在G0/G1期,但MCF-7细胞除外,并且在不同处理的细胞中凋亡细胞百分比增加。CASS下调了细胞周期蛋白A/B1/D1/E1、细胞周期蛋白依赖性激酶-1/2/4/6和p15/16/21/27的表达,但p53除外。观察到蛋白质(细胞色素C、Bax、Bcl-2、p-半胱天冬酶-3、-8、-9和PARP)表达的显著变化,其次是凋亡蛋白酶激活因子-1和生存素。这些发现表明,CASS在治疗人类癌症方面具有抗癌潜力,这使其成为功能性食品中的有力候选物。